Multiple Myeloma

Edward A. Stadtmauer, MD, discusses the evolving treatment landscape in multiple myeloma.

December 9, 2020 — The BCMA-targeted antibody-drug conjugate MEDI2228 showed promising clinical efficacy in patients with relapsed/refractory multiple myeloma, with triple-refractory disease experiencing maintained responses.

Yi Lin, MD, PhD, discusses​s updated results of the phase 1 CRB-401 study in relapsed/refractory multiple myeloma.

Results reported from a group of patients with heavily pretreated multiple myeloma who were administered the combination of selinexor plus pomalidomide and low-dose dexamethasone produced positive responses and provided rationale for further investigation into the regimen.

Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute, of Atrium Health, discusses updated results of the GRIFFIN trial in multiple myeloma.

Panobinostat, given at a 20-mg 3-times-weekly or twice-weekly dosing schedule, in combination with subcutaneous bortezomib and dexamethasone showed durable responses and an acceptable safety profile in patients with relapsed or relapsed/refractory myeloma.

December 7, 2020 - The addition of ixazomib to lenalidomide and dexamethasone resulted in a clinically meaningful 13.5-month improvement in the median progression-free survival of elderly patients with transplant-ineligible newly diagnosed multiple myeloma, although it did not reach statistical significance.

Daratumumab plus lenalidomide, bortezomib, and dexamethasone followed by daratumumab and lenalidomide maintenance showed a statistically significant improvement in response rates and depth of responses when compared to RVd followed by lenalidomide maintenance for patients with transplant-eligible newly diagnosed multiple myeloma.

December 7, 2020 - The addition of subcutaneous daratumumab to pomalidomide and dexamethasone significantly reduced the risk of progression or death by 37%, compared with pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma who had received ≥1 prior line of therapy.

Treatment with the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel was found to yield clinically meaningful improvements in the quality-of-life of triple-class exposed patients with relapsed/refractory multiple myeloma.

CC-92480, a novel oral cereblon E3 ligase modulator agent, plus dexamethasone demonstrated immunomodulatory activity across all dose levels examined in patients with relapsed/refractory multiple myeloma, according to data from the first portion of the ongoing phase 1 CC-92480-MM-001 trial presented during the 2020 ASH Annual Meeting & Exposition.

Ciltacabtagene autoleucel was found to elicit clinically meaningful improvements in health-related quality of life in patients with relapsed/refractory multiple myeloma, and this benefit may become even more pronounced as responses to treatment deepen over time, according to data from the CARTITUDE-1 study presented during the 2020 ASH Annual Meeting & Exposition.

December 6, 2020 - The first-of-its-kind FcRH5xCD3 bispecific antibody cevostamab demonstrated a manageable safety profile with an overall response rate of 53% in heavily pretreated patients with relapsed/refractory multiple myeloma who received active doses.

December 6, 2020 — The off-the-shelf DuoBody® IgG4 PAA binding antibody talquetamab has elicited a high response rate with a tolerable safety profile in heavily pretreated patients with relapsed/refractory multiple myeloma.

December 6, 2020 — REGN5458, a BCMA- and CD3-targeted bispecific monoclonal antibody, demonstrated early, deep, and durable responses with acceptable safety and tolerability in patients with relapsed/refractory multiple myeloma.

December 6, 2020 — The antibody-drug conjugate belantamab mafodotin continued to showcase efficacy and tolerability in heavily pretreated patients with relapsed/refractory multiple myeloma, inducing durable responses even in those who had previously received 7 or more lines of therapy.

December 6, 2020 — The BCMA and CD3 bispecific T-cell redirecting antibody TNB-383B elicited significant responses when administered at a higher dose level and was well tolerated at all doses examined in heavily pretreated patients with relapsed/refractory multiple myeloma.

December 5, 2020 - The addition of belantamab mafodotin to bortezomib and dexamethasone elicited high response rates and a suitable safety profile in patients with relapsed or refractory multiple myeloma.

December 5, 2020 - Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.

ALLO-715, an off-the-shelf chimeric antigen receptor T-cell therapy that targets B-cell maturation antigen, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.

December 5, 2020 - The enriched chimeric antigen receptor T-cell therapy bb21217 improved responses and also prolonged duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.

December 5, 2020 - Patients with heavily pretreated multiple myeloma maintained durable responses with the chimeric antigen receptor T-cell therapy idecabtagene vicleucel in updated findings presented from the phase 1 CRB-401 trial.

December 5, 2020 - A subgroup analysis from the phase 3 BOSTON study demonstrated that once weekly selinexor, bortezomib, and dexamethasone was superior to bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma who had received 1 to 3 prior therapies.

Joseph Mikhael, MD, discusses novel agents used to treat patients with multiple myeloma.

Caitlin Costello, MD, discusses considerations for induction therapy selection in multiple myeloma.